NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
02 April 2025
| Name: | RECCE PHARMACEUTICALS LTD (RCE) | ||||||
| ISIN: | AU000000RCE5 | ||||||
| Date of Listing: | 15 January 2016 | ||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This entity is currently listed and quoted on the Australian Securities Exchange.Legal Status: (updated monthly)
ACN: 124 849 065ABN: 73 124 849 065
Registration Date: 11 April 2007
Capital Gains Tax (CGT) Status: (updated at least quarterly)
To crystallise a capital gain or capital loss on your securities in this entity, you are able to sell your securities on-market in the normal manner. If you determine that the market in your securities is illiquid and you still wish to crystallise a capital gain or loss, kindly contact deListed at admin@delisted.com.au for suggestions as to how you might proceed.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| RECCE PHARMACEUTICALS LTD | 17/01/2018 | |
| RECCE LIMITED | 17/01/2018 |
Automic Registry Pty Ltd
Level 5, 191 ST GEORGES TERRACE PERTH WA 6000
Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
RegistryWebsite RegistryEmail
Expand this box to read and print
The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately following the release by RCE of an announcement regarding the outcome of an application to the Supreme Court of New South Wales. | 12/10/2021 |
The Court made the orders sought by the company, namely: orders taht: the period of 5 business days in which to lodge the cleansing notice be extended to 8 October 2021; and the cleansing notice released on 8 October 2021 be deemed to take effect as if it had been lodged on 2 September 2021; a declaration that any offer for sale, or any sale of, any of the shares occurring in the period after their issue is not invalid by reason of any failure by the company or any shareholder to comply with the disclosure obligations; and orders that any person who made an offer of sale in respect of the shares, and any other person offering to sell or selling the shares is relieved from any civil liability arising out of any contravention in respect of the shares. | 12/10/2021 |
The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement regarding an application to the Supreme Court of New South Wales. | 12/10/2021 |
The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately, following the release by RCE of an announcement regarding anti-viral testing results. | 10/11/2020 |
RECCE 327, a synthetic anti-infective showed encouraging efficacy in an in-vitro screening assay against SARS-CoV-2 virus. This showed encouraging inhibition and is advancing to Stage 1b (confirmatory in vitro testing and a cytotoxicity assessment), underway in near weeks. U.S. in-vivo studies running in parallel are on track for data CY2020. | 10/11/2020 |
The Company requests that the voluntary suspension to remain in place until the earlier of the commencement of normal trading on Wednesday, 11 November 2020 or the release of an announcement by the Company in relation to the results. | 10/11/2020 |
The Company requests that the voluntary suspension to remain in place until the earlier of the commencement of normal trading on Tuesday, 10 November 2020 or the release of an announcement by the Company in relation to the results. | 09/11/2020 |
The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement relating to anti-viral testing results. | 05/11/2020 |
The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately following the release by RCE of an announcement regarding a material research agreement. | 08/07/2020 |
RECCE 327 and New RECCE® 529 compounds were selected for their unique mechanism of actions against hyper-mutation, as indicated on bacteria and viruses (respectively). Testing program will be conducted by CSIRO & University of Melbourne at the Doherty Institute. Therapeutic antiviral treatment focus of RECCE 327 and RECCE 529 may see added potential benefit against secondary bacterial infections. | 08/07/2020 |
The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement regarding a material research agreement. | 08/07/2020 |
name changed from Recce Limited | 17/01/2018 |
The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately following the release by RCE of an announcement regarding the outcome of an application to the Supreme Court of New South Wales. | 12/10/2021 |
The Court made the orders sought by the company, namely: orders taht: the period of 5 business days in which to lodge the cleansing notice be extended to 8 October 2021; and the cleansing notice released on 8 October 2021 be deemed to take effect as if it had been lodged on 2 September 2021; a declaration that any offer for sale, or any sale of, any of the shares occurring in the period after their issue is not invalid by reason of any failure by the company or any shareholder to comply with the disclosure obligations; and orders that any person who made an offer of sale in respect of the shares, and any other person offering to sell or selling the shares is relieved from any civil liability arising out of any contravention in respect of the shares. | 12/10/2021 |
The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement regarding an application to the Supreme Court of New South Wales. | 12/10/2021 |
The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately, following the release by RCE of an announcement regarding anti-viral testing results. | 10/11/2020 |
RECCE 327, a synthetic anti-infective showed encouraging efficacy in an in-vitro screening assay against SARS-CoV-2 virus. This showed encouraging inhibition and is advancing to Stage 1b (confirmatory in vitro testing and a cytotoxicity assessment), underway in near weeks. U.S. in-vivo studies running in parallel are on track for data CY2020. | 10/11/2020 |
The Company requests that the voluntary suspension to remain in place until the earlier of the commencement of normal trading on Wednesday, 11 November 2020 or the release of an announcement by the Company in relation to the results. | 10/11/2020 |
The Company requests that the voluntary suspension to remain in place until the earlier of the commencement of normal trading on Tuesday, 10 November 2020 or the release of an announcement by the Company in relation to the results. | 09/11/2020 |
The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement relating to anti-viral testing results. | 05/11/2020 |
The suspension of trading in the securities of Recce Pharmaceuticals Ltd will be lifted immediately following the release by RCE of an announcement regarding a material research agreement. | 08/07/2020 |
RECCE 327 and New RECCE® 529 compounds were selected for their unique mechanism of actions against hyper-mutation, as indicated on bacteria and viruses (respectively). Testing program will be conducted by CSIRO & University of Melbourne at the Doherty Institute. Therapeutic antiviral treatment focus of RECCE 327 and RECCE 529 may see added potential benefit against secondary bacterial infections. | 08/07/2020 |
The securities of Recce Pharmaceuticals Ltd will be suspended from quotation immediately under Listing Rule 17.2, at the request of RCE, pending the release of an announcement regarding a material research agreement. | 08/07/2020 |
name changed from Recce Limited | 17/01/2018 |
Your browser may reflect a date of printing in American format.
They're registered on Automic not Computershare | 30/04/2020 13:24:35 |
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 22/06/2023 | James Graham | 500,000 | $0.102 | $50,915 |
| 21/06/2021 | Michele Dilizia | -175,000 | $1.019 | $178,239 |
| 16/06/2021 | James Graham | 47,850 | $1.045 | $50,003 |
| 08/08/2019 | Michele Dilizia | -45,000 | $0.222 | $9,975 |
| 07/08/2019 | Michele Dilizia | -277,000 | $0.217 | $60,180 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| John Prendergast | Executive Chairman, Independent Director | 24/04/2018 |
| Justin Reynolds | CFO | 29/11/2017 |
| Alan Dunton | Independent Director | 14/07/2020 |
| Alistair McKeough | Non Exec Director | 01/09/2022 |
| James Graham | Executive Director, CEO | 15/01/2016 |
| Justin Ward | Executive Director | 09/07/2019 |
| Michele Dilizia | Executive Director | 15/01/2016 |
| Maggie Niewidok | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Graham Melrose | Executive Director | 15/01/2016 | 03/07/2020 |
| Peter Williams | CFO | 15/01/2016 | 29/11/2017 |
| Dominic Barnes | Independent Director | 16/05/2016 | 21/01/2017 |
| Bernadette Murdoch | Independent Director | 27/05/2016 | 22/11/2016 |
| Ian Brown | Non Exec Director | 15/01/2016 | 10/04/2016 |
| Dongke Zhang | Non Exec Director | 15/01/2016 | 10/04/2016 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
